China Merger Control Filing for Foreign Deals: When SAMR Notification May Be Required

China Merger Control Filing for Foreign Deals: When SAMR Notification May Be Required

A foreign-to-foreign acquisition can still require a China merger control filing. For boards, deal teams, and overseas counsel, the practical question is not whether the target is incorporated in China, but whether the transaction gives control or decisive influence over a business with enough China turnover to trigger filing with the State Administration for Market Regulation (SAMR).

That point is often missed in cross-border deals because the buyer’s diligence workstream focuses first on corporate ownership, sanctions, tax, employment, intellectual property, and regulatory licenses in the target’s home jurisdictions. China antitrust filing gets raised too late, sometimes only after signing, when the parties are already talking about long-stop dates, integration steps, and covenants to preserve business continuity. If the China filing screen starts late, the legal issue quickly becomes a timetable issue.

For foreign investors, a useful starting rule is simple: not every offshore deal needs a China filing, but many offshore deals should be screened for one early. The screening should sit next to the broader transaction diligence work already discussed in this guide to cross-border M&A due diligence in China and, where the transaction is part of a wider China entry strategy, the earlier structural choices covered in this article on choosing between a joint venture and a WFOE in China.

Start with the right trigger analysis: control matters as much as turnover

China merger control filing is not limited to mergers between Chinese entities. Under China’s antitrust framework, a concentration can arise when undertakings merge, when one undertaking acquires control over another through equity or assets, or when control or decisive influence is obtained through contracts or other arrangements. In practical deal terms, that means the filing question can arise in share acquisitions, asset acquisitions, joint ventures, step acquisitions, and governance restructurings where veto rights or board control materially change who directs the business.

Foreign parties often misread the analysis by treating ownership percentage as the only test. Percentage matters, but it is not the entire question. Deal counsel should also look at governance rights, board appointment rights, reserved matters, budget approval power, information rights tied to strategic influence, and whether the buyer will be able to determine or block key commercial decisions after closing. A minority investment can still raise a filing question if the rights package amounts to control or decisive influence.

The second part of the screen is turnover. Under the current filing-threshold regulation revised in January 2024, a filing is generally required before implementation if either of two thresholds is met: the parties’ combined worldwide turnover in the previous financial year exceeds RMB 12 billion and at least two parties each had China turnover above RMB 800 million, or the parties’ combined China turnover exceeds RMB 4 billion and at least two parties each had China turnover above RMB 800 million. For global deal teams, the practical lesson is that a target with relatively modest China operations can still be part of a notifiable deal when the buyer group is large and both sides have meaningful China revenue.

There is another important point for foreign investors: even if the standard thresholds are not met, SAMR may require a filing where there is evidence that the concentration has or may have the effect of eliminating or restricting competition. That does not mean every small deal becomes uncertain, but it does mean counsel should be cautious in sectors where market structure, technology access, data, or supply-chain position could create a concentrated competitive effect that is disproportionate to current turnover.

Red-flag checklist for the first filing screen:

• Does the transaction change who can control the target, appoint directors, or veto strategic decisions?
• Are there at least two transaction parties with significant China turnover in the last financial year?
• Is the target offshore on paper but commercially active in China through sales, subsidiaries, distributors, digital channels, or licensing?
• Is the deal part of a series of steps that could be reviewed together rather than in isolation?
• Does the sector involve concentrated technology, inputs, platforms, or regulatory sensitivity that could attract closer scrutiny?

Run the China filing workstream early instead of leaving it to signing-week cleanup

For foreign buyers, the most expensive mistake is not usually a wrong legal theory in the abstract. It is failing to organize the facts needed for the filing screen early enough. China merger control analysis depends on data that is often scattered across finance, group legal, local business teams, and target management. If deal counsel waits until signing week to ask for China revenue segmentation, affiliate maps, or copies of governance documents, the filing issue becomes a closing-delay problem.

A practical workstream usually starts with three internal maps. The first is the transaction map: what exactly is being acquired, in what steps, and what rights change at each step. The second is the group map: which entities belong to the buyer and seller groups for turnover purposes. The third is the China nexus map: where the parties earn China revenue, which entities book it, and whether the target has subsidiaries, customers, distributors, digital sales, or licensing income linked to China. These three maps should be tested together. A formally offshore target may still have a meaningful China nexus once the group picture is reconstructed properly.

Deal documents should also be drafted with the filing timetable in mind. If filing is plausible, the signing package should contain cooperation covenants, information-sharing obligations, a realistic long-stop date, and a clean rule that the parties will not complete the relevant closing steps before clearance when filing is required. Some transactions fail here because the SPA says the parties will use “reasonable efforts,” but says very little about who prepares market data, who controls third-party responses, who bears remedy risk, or whether pre-closing operational integration is restricted.

Foreign investors should also remember that China law recognizes narrow internal-group situations where no filing is required, such as where one participating undertaking already holds more than 50 percent of the voting shares or assets of every other participating undertaking, or where more than 50 percent of the voting shares or assets of each participating undertaking is already held by the same non-participating undertaking. Those exceptions are useful, but they are not a substitute for a disciplined control analysis. Internal restructurings still need to be checked carefully against the actual chain of ownership and rights.

Documents worth collecting before the first China filing call:

• The current and post-closing cap table, governance chart, and key shareholder or JV agreements.
• Audited financial statements and China turnover breakdown for the previous financial year.
• A list of China entities, branches, distributors, licensing channels, and major China-facing business lines.
• Draft signing and closing mechanics showing which steps occur before and after clearance.
• A short internal note identifying competitor, vertical, platform, or technology overlaps that may matter in China.

Plan for filing materials, review timing, and simplified-case analysis

Once a filing becomes likely, the next question is not only whether to notify, but how to manage timing realistically. According to SAMR’s published service guidance, filing documents and materials must be complete before formal acceptance, and the submission must be in Chinese. The filing package generally includes the notification form, a competition-impact explanation, the concentration agreement and related documents, the previous financial year’s audited financial statements, and other materials requested by the authority. The authority also expects public and confidential versions of the filing materials where confidentiality is claimed.

This matters because the legal review clock does not solve poor internal preparation. The authority’s published process contemplates an initial review period of 30 days from formal acceptance, a further review period of up to 90 days where deeper review is opened, and a possible extension of up to 60 days in statutory circumstances. There is also a mechanism to suspend the review clock in certain situations, such as where required materials are not provided or important new facts need to be checked. For transaction planning, the safe lesson is that formal statutory periods are only one part of the timetable; pre-acceptance preparation and information quality can be just as important.

Some foreign deals may qualify for the simplified procedure. SAMR’s public FAQ states that simplified treatment can apply in several situations, including certain low-share overlap cases, offshore joint ventures that do not conduct business in China, offshore acquisitions of targets that do not conduct business in China, and certain shifts from joint to sole control. But simplified treatment is a legal conclusion, not a label the parties can assign themselves for convenience. Counsel should test the actual facts carefully, especially where a target has China sales through indirect channels, licensing arrangements, or online distribution that business teams initially overlook.

Because filing materials are document-heavy and often need Chinese-language preparation, experienced deal teams usually assign a dedicated owner for data collection, a separate owner for market narrative, and a clear approval chain for factual signoff. Without that structure, the filing workstream gets delayed by repeated requests to finance, contradictory market descriptions from different business units, and late discoveries that key annexes are unsigned or incomplete.

Common mistakes in foreign deals with a China filing angle

The most common operational failure is treating China merger control as a post-signing formality rather than a gating item. Once that mindset takes hold, the deal documents, closing steps, internal communications, and integration planning all begin to move on assumptions that may not be safe.

Common mistakes include:

• Looking only at incorporation and ignoring China revenue. Offshore targets can still have enough China nexus to trigger filing analysis.
• Equating control with majority ownership. Board, veto, and governance rights can change the answer.
• Collecting turnover data too late. China revenue mapping often takes longer than deal teams expect.
• Assuming “simplified case” before verifying the facts. Indirect China business can break that assumption.
• Signing a timetable that does not leave room for acceptance and review. The legal issue then becomes a commercial delay issue.
• Starting integration too early. Parties should avoid implementing closing-sensitive steps before required clearance.
• Underestimating exposure for failure to file. China law allows investigation and can lead to remedies, unwind-style measures, or fines depending on the case.

Talk to a China Business Lawyer before the filing issue becomes a closing problem

For foreign companies buying, combining, or restructuring businesses with a China nexus, the right time to run the merger-control screen is early enough to shape the deal timetable, not after the documents are largely fixed. A disciplined review of control rights, turnover mapping, simplified-case eligibility, filing materials, and closing covenants can often prevent a manageable regulatory issue from becoming an execution problem.

If your transaction team is assessing a China-facing acquisition, joint venture, carve-out, or governance restructuring, it may be useful to talk to a China business lawyer before signing or before assuming the deal can close on the original timetable.

---

This article is general information, not legal advice. For advice on your situation, please get in touch.

About the author: Jianxing Pan is a lawyer and partner at Beijing Chang’an Law Firm (Beijing/Shenzhen) and previously served as director of the firm’s Shenzhen office. His practice spans intellectual property, dispute resolution, corporate law, and cross-border compliance and tax-audit matters, and he serves as standing legal counsel to numerous enterprises and individuals. He pairs a solid command of the law with extensive practical experience, focusing on the issues that decide a case to secure the best possible outcome for clients. To discuss a specific matter, you are welcome to get in touch through the contact details on this site.

Jianxing Pan, Attorney · Beijing Chang’an Law Firm (Beijing/Shenzhen)
Focus areas: Securities Litigation · Intellectual Property · Dispute Resolution · Cross-Border Compliance
July 2026